mAID-Tag (F4L5V) Rabbit Monoclonal Antibody #28723
- WB
Product Specifications
| REACTIVITY | All |
| SENSITIVITY | Transfected Only |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- All-All Species Expected
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
The AID system has been adapted and improved since its introduction. The minimum sequence of auxin-responsive protein IAA17 necessary for the degron response was identified within amino acids Lys65-Lys132, dubbed mini-AID (mAID), allowing for increasingly smaller insertion sequences over time (6,7). More recently, the AID2 modifications improved the efficiency of the mAID system with the co-expression of a modified Oryza sativa E3 ligase TIR1 (OsTIR1), along with the use of a high-potency ligand 5-phenyl-indole-acetic acid (5-Ph-IAA) (8,9). Precise control of OsTIR1 expression during the cell cycle allows for phase-specific deletion of proteins of interest (10). Researchers have utilized CRISPR/Cas9-mediated homology-directed repair (HDR) to introduce homozygous knock-ins of mAID-tags to proteins of interest (11).
- Gray WM et al. (1999) Genes Dev 13, 1678-91.
- Gray WM et al. (2001) Nature 414, 271-6.
- Nishimura K et al. (2009) Nat Methods 6, 917-22.
- Holland AJ et al. (2012) Proc Natl Acad Sci USA 109, E3350-7.
- Pujadas Liwag EM et al. (2024) Genome Biol 25, 77.
- Kubota, T. et al. (2013) Mol Cell 50, 273-80.
- Morawska, M. and Ulrich, H.D. (2013) Yeast 30, 341-51.
- Yesbolatova, A. et al. (2020) Nat Commun 11, 5701.
- Saito Y and Kanemaki MT (2021) Curr Protoc 1, e219.
- Capece M et al. (2023) Cell Death Differ 30, 2078-2091.
- Adhikari B et al. (2021) STAR Protoc 2, 100949.
Alternate Names
At1g04250; AUX/IAA transcriptional regulator family protein; AXR3; F19P19.31; IAA17
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.